Freenome Reports Third Quarter 2026 Financial Results
Globe Newswire•10/11/2026•16:01 ET
0
Key Highlights
- ➤Q3 revenue $183.5 million, up from $1.0 million year over year
- ➤Q3 GAAP net income $60.1 million versus $64.5 million loss
- ➤FDA approval for SimpleScreen CRC triggered a $100 million milestone payment
- ➤IPO raised approximately $310 million in gross proceeds on Nasdaq
- ➤2026 revenue guidance set at $192 million to $194 million
Expert Statements
Aaron Elliott, CEO of Freenome
“Freenome made meaningful progress in its first quarter as a public company, executing on our strategic partnerships and strengthening our operating foundation.”
Aaron Elliott, CEO of Freenome
“With SimpleScreen CRC approved by the FDA and our lung program advancing, we remain focused on expanding access to blood-based early cancer detection.”
Aaron Elliott, CEO of Freenome
“Looking ahead, we believe the opportunity is substantial as our multiomics AI platform positions us to build a portfolio of single-cancer and multi-cancer tests that has the potential to truly transform how cancer is detected.”
– Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC –
– Entered the public market and raised gross proceeds of $310 million –
Get started
Create a free account to read the full story.